Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25185787 | 0.87 | CTRB1 (0.51) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL5562292 | 0.87 | CTRB1 (0.51) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL9219338 | 0.84 | CTSK (0.62) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL19485480 | 0.84 | CTSK (0.62) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL5566516 | 0.83 | SYK (0.45) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL6781311 | 0.83 | CTSK (0.58) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL5887598 | 0.82 | P2RX7 (0.59) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL5887595 | 0.82 | P2RX7 (0.59) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL5566427 | 0.82 | SYK (0.45) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL7455995 | 0.82 | SYK (0.51) | SYKCTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240161-B1 | THIENYLALANINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA GMBH (DE) | 2007-04-18 | — | — | EP | disclosed |
| US-6762190-B2 | VITRONECTIN RECEPTOR ANTAGONISTS; SUPPRESSING OSTEOCLAST BONE RESORPTION; PREVENTING ANGIOGENESIS OR VASCULAR SMOOTH MUSCLE PROLIFERATION | AVENTIS PHARMA S.A. DEUTSCHLAND GMBH GENENTECH, INC. (DE) | 2004-07-13 | — | — | US | disclosed |
| US-20030105080-A1 | Thienylalanine derivatives as inhibitors of cell adhesion | AVENTIS PHARMA S.A. DEUTSCHLAND GMBH (DE) | 2003-06-05 | — | — | US | disclosed |
| EP-1240161-A1 | THIENYLALANINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001044237-A1 | THIENYLALANINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-06-21 | — | — | WO | disclosed |
| EP-1108721-A1 | Thienylalanine derivatives as inhibitors of cell adhesion | Aventis Pharma Deutschland GmbH (DE) | 2001-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105080-A1 | Thienylalanine derivatives as inhibitors of cell adhesion | VCAM1, TEK, ADGRF1 | SYK 1469/4885CTSK 2453/4885CTSS 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.